Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at HC Wainwright from $2.00 to $54.00. They now have a "buy" rating on the stock.
HighReport
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at HC Wainwright from $2.00 to $54.00. They now have a "buy" rating on the stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $39.00 price target on the stock.
HighReport
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $39.00 price target on the stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $42.00 price target on the stock.
MediumReport
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $42.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: